A Randomised, Parallel-group, Open-label Phase II Trial of the Immunological Effects of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer Patients Who Have Achieved Response or Disease Stability With First-line Chemotherapy

Trial Profile

A Randomised, Parallel-group, Open-label Phase II Trial of the Immunological Effects of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer Patients Who Have Achieved Response or Disease Stability With First-line Chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs GX 301 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Laboratoires Leurquin-Mediolanum
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Dec 2015 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018 as per ClinicalTrials.gov record.
    • 23 Dec 2015 Planned primary completion date changed from 1 May 2016 to 1 May 2017 as per ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top